Study M530
Study name | Bansal R 2019 |
Title | Effects of the antidepressant medication duloxetine on brain metabolites in persistent depressive disorder: a randomized, controlled trial |
Overall design | The aim of this study was to assess whether patients with persistent depressive disorder (PDD) have abnormal levels of N-acetyl-aspartate and whether those levels normalize following treatment with the antidepressant medication duloxetine. The authors acquired proton magnetic resonance spectroscopic imaging (MRSI) data on a 3 Tesla, GE Magnetic Resonance Imaging scanner in 41 patients with PDD (PDD group) at two time points: baseline and at the end of a 10-week, placebo-controlled, double-blind, randomized controlled trial of the antidepressant medication duloxetine. Patients were randomized such that 21 patients received the active medication (PDD + duloxetine group) and 20 patients received placebo. In addition, the authors acquired MRSI data once in 29 healthy controls (control group). Metabolite quantification was normalized by background noise. |
Study Type | Type1; Type2; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-5 diagnosed persistent depressive disorder, HAMD-24 >= 12 |
Sample size | 70 |
Tissue | Central; Brain; Brain; |
Platform | MRS; MRS: 3 T GE Signa MRI scanner; |
PMID | |
DOI | |
Citation | Bansal R, Hellerstein DJ, Sawardekar S, et al. Effects of the antidepressant medication duloxetine on brain metabolites in persistent depressive disorder: a randomized, controlled trial. PLoS One. 2019;14(7):e0219679. |
Metabolite |
